Latest Market Access News

EBR Systems marked a pivotal transition in 2025 with FDA approval of its WiSE CRT System and the initiation of U.S. commercial implants, generating $1.6 million in revenue. Despite this progress, the company reported a net loss of $48.8 million and completed a significant capital raise to support ongoing growth.

ARC Funds Limited’s trading suspension has been lifted following key announcements about new board appointments, signaling a fresh chapter for the investment manager.

dorsaVi has secured significant commercial and clinical milestones with new elite sports and European clinical partnerships, showcasing its advanced real-time AI sensor technology.

EMVision Medical Devices has secured a $3.8 million R&D tax rebate and gained approval to claim rebates on overseas expenditures, strengthening its financial footing as it advances clinical trials for its neurodiagnostic device.

Alliance Nickel is advancing its NiWest project by exploring vat leaching to reduce capital costs and has completed initial gold drilling at Wanbanna, while continuing offtake talks with Stellantis and considering a NASDAQ listing via de-SPAC.

Titomic Limited is planning to redomicile from Australia to the United States, aiming to deepen its footprint in the US defense and aerospace sectors and pursue a US stock exchange listing.

EVE Health Group has completed R&D on multiple reformulated drug candidates targeting major sexual health and cardiovascular markets, preparing patent filings and licensing strategies to capitalise on a combined $30 billion global opportunity.

Rhythm Biosciences has achieved a significant regulatory milestone with NATA accreditation for its ColoSTAT® blood-based colorectal cancer test, enabling its commercial rollout in Australia and strengthening reimbursement prospects.

Pearl Gull Iron Limited has been suspended from ASX trading after failing to meet operational requirements, raising questions about its future on the exchange.

Neuren Pharmaceuticals’ partner Acadia Pharmaceuticals is seeking a re-examination of the European Medicines Agency’s refusal to approve trofinetide for Rett syndrome, aiming to overturn the setback and bring the treatment to European patients.

Murray Cod Australia Ltd reported a 40% revenue increase to $6.69 million for H1 2026 but swung to a $4.06 million net loss, reflecting significant investments and operational expansion.

De.mem Limited reported a 20% increase in revenue to $29.9 million for FY2025, alongside a reduced net loss and its first full-year positive adjusted EBITDA. The company also completed the acquisition of Core Chemicals, expanding its specialty chemicals footprint in the gold mining sector.